Nausea parathyroid hormone

Reviews of parathyroid hormone have suggested that it is generally well tolerated (4,5,6). The adverse effects of parathyroid hormone that have been reported in clinical trials are mild and include transient bone pain, nausea, dizziness and local irritation at the injection site (7). Hypercalcemia, which is common, is usually mild and asymptomatic. Adverse effects, including hypercalcemia, appear to be dose related in the therapeutic range. 

Parathyroid hormone has potent anabolic effects on the skeleton if given intermittently being used in clinical trials. Initial concerns about the development of osteosarcoma in rats after prolonged treatment with high doses of parathyroid hormone have not been confirmed in human trials, but surveillance continues (8). In one study there was a mild increase in creatinine, which was thought not to have clinical significance (9). Mild nausea (10) and arthralgia (10,11) have also been reported. 

Nausea was reported in 18% and headache in 13% of 552 women who took parathyroid hormone 40 micrograms, compared with 8% of the 544 women who took placebo (12). 

Teriparatide Parathyroid hormone Osteoperosis Nausea, injection site reactions... 

Randomised trials A randomised, controlled trial of 6 months of parathyroid hormone treatment in combination with either concurrent or sequential ibandronate over 2 years [67 ] found that both treatment regimens were efficacious in increasing bone mineral density in postmenopausal women (N = 44). Seven women met the criteria for hypercalcaemia, with only one requiring reduction in treatment. Three women met the criteria for hypercalciuria. The most commonly reported adverse events were nausea (32%) and injection-site reactions (32%). 

---